Maranda Eversoll, NP
Family · Flowood, MSNPI 1376072413
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,574 of the $196,550 with a category attached, or 60.3%. Johnson & Johnson accounts for 67.1% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $130,137, more than ten times the $1,778 reported in 2021. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 904 payments — averaging $217.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$132K
- Takeda Pharmaceuticals U.S.A., Inc.$26K
- AbbVie$17K
- Lilly USA, LLC$6K
- Celltrion USA Inc.$3K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $10K from 25 others
Across 11 payments — averaging $263.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$13,9327%
- Speaking & faculty fees$118,57460%
- Travel & lodging$45,33223%
- Food & beverage$18,4179%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 274 | $131,836 |
| Takeda Pharmaceuticals U.S.A., Inc. | 103 | $25,532 |
| AbbVie | 189 | $16,796 |
| Lilly USA, LLC | 25 | $5,667 |
| Celltrion USA Inc. | 17 | $3,383 |
| E.r. Squibb & Sons, L.L.C. | 10 | $2,929 |
| Genentech USA, Inc. | 4 | $2,768 |
| Pfizer | 25 | $1,540 |
| Janssen Scientific Affairs, LLC | 25 | $1,518 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 111 | $1,400 |
| Bristol Myers Squibb | 45 | $1,052 |
| Merck | 11 | $800 |
| Intercept Pharmaceuticals, Inc. | 13 | $251 |
| Phathom Pharmaceuticals, Inc. | 7 | $178 |
| Pharmacosmos Therapeutics Inc. | 3 | $154 |
| Boehringer Ingelheim | 8 | $125 |
| Ferring Pharmaceuticals Inc. | 7 | $91 |
| Ardelyx, Inc. | 4 | $76 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $59 |
| Braintree Laboratories, Inc. | 3 | $50 |
| Ironwood Pharmaceuticals, Inc | 3 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| UCB, Inc. | 1 | $30 |
| Amgen | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Evoke Pharma, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| QOL Medical, LLC | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$196,550 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 656 | $18,029,509 |
| RemicadeInfliximab | 125 | $1,173,464 |
| EntyvioVedolizumab | 102 | $869,208 |
| Skyrizi On-BodyRisankizumab-Rzaa | 27 | $571,524 |
| Humira(Cf) PenAdalimumab | 49 | $559,796 |
| RinvoqUpadacitinib | 44 | $368,269 |
| SkyriziRisankizumab-Rzaa | 18 | $176,007 |
| XeljanzTofacitinib Citrate | 12 | $69,542 |
| AvsolaInfliximab-Axxq | 14 | $52,172 |
| Mesalamine | 77 | $24,903 |
| LinzessLinaclotide | 19 | $18,176 |
| Mesalamine ErMesalamine | 63 | $11,901 |
| Budesonide DrBudesonide | 25 | $2,934 |
| Dexlansoprazole DrDexlansoprazole | 17 | $2,359 |
| Balsalazide Disodium | 22 | $2,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $131,836 | $19,202,972781 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $25,532 | $869,208102 claims |
| AbbVieRinvoq, Skyrizi, Linzess | $16,796 | $562,45281 claims |
| PfizerXeljanz | $1,540 | $69,54212 claims |
| AmgenAvsola | $24 | $52,17214 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $22 | $978220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Flowood
- Ashley CocilovaFlowood$72K
- Tina GreggFlowood$20K
- Christina PerkinsFlowood$14K
- Jordan SmithFlowood$12K
- Shara BeckwithFlowood$12K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.